Market Cap | 4.64B | P/E | - | EPS this Y | 87.50% | Ern Qtrly Grth | -61.50% |
Income | 385.71M | Forward P/E | 13.12 | EPS next Y | -3.00% | 50D Avg Chg | -9.00% |
Sales | 1.51B | PEG | 0.41 | EPS past 5Y | 25.67% | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 3.63 | EPS next 5Y | 24.80% | 52W High Chg | -17.00% |
Recommedations | 2.40 | Quick Ratio | 2.42 | Shares Outstanding | 164.67M | 52W Low Chg | 29.00% |
Insider Own | 1.31% | ROA | 8.62% | Shares Float | 156.26M | Beta | 0.42 |
Inst Own | 112.37% | ROE | 30.08% | Shares Shorted/Prior | 18.62M/17.70M | Price | 27.95 |
Gross Margin | 83.31% | Profit Margin | 19.15% | Avg. Volume | 1,405,774 | Target Price | 34.92 |
Oper. Margin | 27.53% | Earnings Date | Jul 24 | Volume | 2,776,204 | Change | -2.07% |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
LAURENCIN CATO T | Director Director | Jun 07 | Sell | 31.5 | 2,800 | 88,200 | 7,479 | 06/07/23 |
LAURENCIN CATO T | Director Director | Jun 07 | Option | 22.97 | 2,800 | 64,316 | 10,279 | 06/07/23 |
Nichols Christian Todd | SVP, Chief Commercia.. SVP, Chief Commercial Officer | May 30 | Sell | 28.93 | 27,134 | 784,987 | 40,984 | 05/30/23 |
Nichols Christian Todd | SVP, Chief Commercia.. SVP, Chief Commercial Officer | May 30 | Option | 20.43 | 19,634 | 401,123 | 68,118 | 05/30/23 |
Nichols Christian Todd | SVP, Chief Commercia.. SVP, Chief Commercial Officer | Jun 21 | Sell | 28.2584 | 7,474 | 211,203 | 21,035 | 06/21/22 |
POPS RICHARD F | Director and CEO, Al.. Director and CEO, Alkermes plc | May 05 | Option | 16.55 | 450,000 | 7,447,500 | 1,062,046 | 05/06/22 |
POPS RICHARD F | Director and CEO, Al.. Director and CEO, Alkermes plc | May 05 | Sell | 28.13 | 347,257 | 9,768,339 | 968,299 | 05/06/22 |
Cooke Shane | Director Director | Apr 11 | Option | 16.55 | 10,000 | 165,500 | 100,478 | 04/12/22 |
Cooke Shane | Director Director | Apr 11 | Sell | 29.26 | 10,000 | 292,600 | 90,478 | 04/12/22 |
Cooke Shane | Director Director | Apr 04 | Option | 16.55 | 10,000 | 165,500 | 100,478 | 04/05/22 |
Cooke Shane | Director Director | Apr 04 | Sell | 28.18 | 10,000 | 281,800 | 90,478 | 04/05/22 |
Hopkinson Craig C. | EVP R&D, Chief Medic.. EVP R&D, Chief Medical Officer | Feb 23 | Sell | 24.7559 | 11,983 | 296,650 | 17,994 | 02/24/22 |
Hopkinson Craig C. | EVP R&D, Chief Medic.. EVP R&D, Chief Medical Officer | Feb 18 | Sell | 25.17 | 2,306 | 58,042 | 9,496 | 02/23/22 |
ANSTICE DAVID W | Director Director | Jun 08 | Option | 14.6 | 5,000 | 73,000 | 78,081 | 06/08/21 |
DIXON WENDY L | Director Director | Apr 20 | Option | 14.6 | 25,000 | 365,000 | 61,600 | 04/20/21 |
DIXON WENDY L | Director Director | Apr 20 | Sell | 20 | 25,000 | 500,000 | 36,600 | 04/20/21 |
Brown Iain Michael | SVP, Chief Financial.. SVP, Chief Financial Officer | Apr 20 | Option | 18.11 | 35,000 | 633,850 | 83,154 | 04/20/21 |
Brown Iain Michael | SVP, Chief Financial.. SVP, Chief Financial Officer | Apr 20 | Sell | 19.99 | 35,000 | 699,650 | 48,362 | 04/20/21 |
DIXON WENDY L | Director Director | Jan 15 | Option | 12.62 | 35,000 | 441,700 | 36,600 | 01/15/21 |